Skip to main content

Table 2 Top 10 CKD-related research priorities resulting from the in-person workshop vs. online wiki-based groups

From: A randomized controlled trial comparing in-person and wiki-inspired nominal group techniques for engaging stakeholders in chronic kidney disease research prioritization

In-person workshop group

Wiki rank

Online wiki-based group

Workshop rank

1. What are the most effective new interventions and treatments to prevent the development and progression of kidney disease?

1

1. What are the most effective new interventions and treatments to prevent the development and progression of kidney disease?

1

2. What is the best diet to slow progression of kidney disease and what are the benefits and risks of specific diets (ie phosphate restriction, protein restriction, low salt etc.) in terms of kidney disease progression and quality of life?

6

2. What are the harmful effects of medications used in patients with CKD, and in particular, the combinations of medications used to treat other diseases (such as diabetes and high blood pressure)?

7

3. What are the causes of symptoms in patients with chronic kidney disease, including fatigue, low energy, sleeping problems, depression, anxiety and sexual dysfunction, and how can these best be treated to improve quality of life?a

8

3. What are the best signs or markers (ie blood tests, urine tests or other tests) to identify and diagnose kidney disease early?

14

4. What are the optimal strategies, such as having access to health information (eg lab test results), sharing of information, and/or improving communication, to help patients manage their health condition(s) themselves and to improve patient experience and outcomes?

Not ranked in the top 10

4. What are the benefits and risks associated with use of vitamins, supplements and alternative/complementary therapies (ie herbal, naturopathic, marijuana etc.) in terms of kidney disease progression and quality of life?

11

5. What is the impact of lifestyle factors (ie exercise, stress) on risk of developing kidney disease, kidney disease progression, and quality of life?

9

5. How can we predict how fast kidney function will get worse, and when kidneys will fail?

13

6. What are the optimal strategies for the management of CKD (ie those undertaken by the primary care physician, nephrologist, other health care professionals) to delay progression and improve outcomes?

Not ranked in the top 10

6. What is the best diet to slow progression of kidney disease and what are the benefits and risks of specific diets (ie phosphate restriction, protein restriction, low salt etc.) in terms of kidney disease progression and quality of life?

2

7. What are the harmful effects of medications used in patients with CKD, and in particular the combinations of medications used to treat other diseases (such as diabetes and high blood pressure)?

2

7. What are the optimal medications (eg ACE inhibitors, ARBs, phosphate binders, sodium bicarbonate, etc.) to slow progression of kidney disease?

19

8. What are the optimal approaches for the prevention and treatment of cardiovascular disease in patients with CKD?

Not ranked in the top 10

8. What are the causes of symptoms in patients with chronic kidney disease, including fatigue, low energy, sleeping problems, depression, anxiety and sexual dysfunction, and how can these best be treated to improve quality of life?a

3

9. What is the best strategy (eg screening, programs targeting high risk groups, programs to increase public awareness) to identify kidney disease early?

Not ranked in the top 10

9. What is the impact of lifestyle factors (ie exercise, stress) on risk of developing kidney disease, kidney disease progression, and quality of life?

5

10. How do we ensure that patients with CKD have equitable access to care (eg nephrologists, allied health clinics) irrespective of location of residence or socio-economic status?

Not ranked in the top 10

10. How can communication regarding patient care be improved and/or streamlined across all disciplines (primary care, nephrology, allied health) to improve outcomes and the patient experience?

12

  1. CKD chronic kidney disease, ACE angiotensin-converting enzyme, ARB angiotensin II receptor blockers
  2. aItem subsumed a second uncertainty noted within the top 30 uncertainties in both the in-person and wiki groups